Loading clinical trials...
Loading clinical trials...
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer
Conditions
Interventions
Carboplatin
Durvalumab
+10 more
Locations
2
United States
City of Hope
Duarte, California, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Start Date
December 6, 2021
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
June 4, 2025
NCT06498635
NCT06122064
NCT04751747
NCT05502523
NCT05624996
NCT03948100
The Ohio State University Comprehensive Cancer Center
CONTACT
800-293-5066OSUCCCClinicaltrials@osumc.eduLead Sponsor
Ohio State University Comprehensive Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions